Account Intelligence Report Takeda Pharmaceutical

Transcript:Account Intelligence Report Takeda Pharmaceutical:
Account Intelligence Report Takeda Pharmaceutical Company Limited Business Overview Business Segments Financials Performance By Therapeutic Area By Geography Strategies and Challenges Business Strategy Business Challenges IT strategy Latest Strategic Initiatives Peer Benchmarking Key Stakeholders Key IT Outsourcing Vendors Table of Contents Business Overview Takeda Pharmaceutical Company Limited (Takeda) is a global biopharmaceutical firm primarily engaged in research, development, production and commercialization of pharmaceutical products, over-the-counter (OTC) medicines, quasi drug consumer products and other health care products. The company’s business operations are focused on four therapeutic areas including gastroenterology (GI), oncology, rare diseases and Neuroscience. Takeda operates through single business segment, however, the company generates 78.6% of its revenue from five key business areas namely, Gastroenterology (GI), Rare Diseases, PDT Immunology, Oncology and Neuroscience. Takeda delivers its products under 14 global brands namely, ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG. During FY2020, the company invested JPY492.4 billion (14.96% of the total revenue) in its research and development activities. Geographically, the company’s business operations are spread across 80 countries. The majority of the company’s revenue is generated from Japan and the United states. Takeda is headquartered in Tokyo, Japan. Gastroenterology Oncology Takeda operates in five business areas PDT Immunology Rare Diseases Neuroscience Business Areas Business Areas Financial Performance In FY2020, the company reported revenue of JPY3,291.2 billion, up 56.9% on an annual basis from JPY2097.2 billion in FY2019. This increase in top-line performance was due to the revenue from the products obtained through the acquisition of Shire Plc. However, Takeda registered a poor bottom line performance in FY2020. The company’s operating profit declined by 57.7% as compared to FY2019 from JPY237.7 billion to JPY100.4 billion in FY2020. Its net income dropped by 67.2% as compared to previous year from JPY135.1 billion in FY2019 to JPY44.3 in FY2020. Financial Performance by Therapeutic Area In FY2020, the company generated JPY697.9 billion revenue from GI therapeutic area and recorded an increase of 29.4% over FY2019. This was primarily due to the company’s top selling product ENTYVIO. GI business contributed 21% of Takeda’s total revenue. Similarly, the Rare Diseases, PDT, Oncology and Neuroscience business areas recorded JPY634.9 billion (19%), JPY394.6 billion (12%), JPY421 billion (13%), and JPY438.5 (13%) billion revenue respectively. Apart from therapeutic areas, the company’s others business operation generated JPY704.8 revenue and accounted for 22% of Takeda’s total revenue. Financial Performance by Geography Geographically, Takeda’s